Showing posts with label Obama. Show all posts
Showing posts with label Obama. Show all posts

Obama's Executive Order Spurs Drug Industry to Cooperate with FDA to Ease Drug Shortages

This week marks the six-month anniversary of President Obama signing an Executive Order to help FDA in its efforts to prevent and resolve prescription drug shortages. Following the Executive Order, FDA sent out letters to drug manufacturers asking them to "voluntarily report to FDA if they saw the emerging potential for a drug shortage."

"I am both amazed and delighted to see the progress that’s been made," said FDA Commissioner Margaret Hamburg in a blog post (here). "Early notification to FDA of potential disruptions in drug supply has made a huge difference in our efforts -- and the numbers really tell the story [see chart below]."


"Since reaching out to industry, there has been a six-fold increase in early notifications from manufacturers," said Hamburg. "Also in that six month timeframe, we have been able to prevent 128 drug shortages, and we’re seeing fewer numbers of shortages occur – 42 new drugs in shortage reported in 2012, compared to 90 new shortages at this time last year. This data is a testament to how FDA exercises flexibility and discretion in much of our work on drug shortages and the importance of strong collaboration and constant communication with industry, health professionals, and patients."

According to the above chart, FDA projects that there will be only about 130 actual drug shortages reported in 2012 compared to 250 reported in 2011 and that FDA-industry cooperation will have prevented about 100 additional shortages. By FDA estimates, even if it didn't prevent any shortages, the number of drug shortages in 2012 would be about 230 compared to 250 in 2011. That is, FDA envisions the trend in drug shortages reversing with or without FDA intervention.

But with FDA and industry cooperation, there were only 42 new drugs in shortage reported in 2012, compared to 90 new shortages at this time last year.

Pharma's ObamaCare Math: It All Adds Up, But...

Drug companies are already claiming a loss of income due to costs related to the new U.S. health-care overhaul (aka, "ObamaCare"). First, Lilly claimed costs associated with higher rebates to the Medicaid government health program for the poor, etc. will reduce its 2010 revenue by $350 million to $400 million. Then, Johnson & Johnson said its 2010 revenue would be cut between $400 million and $500 million (see "Pharma Sales Set to Grow 5%-8%; Overhaul Effects Unclear").

It seems that the top 20 pharma companies got together and decided how to divvy up the $80 Bn that Billy Tauzin promised the drug industry would kick in to help pay for health care reform over 10 years. If each of these 20 companies claim losses of about $400 million per year for ten years, it all adds up to -- you guessed it: $80 billion!

Not included in these calculations is the 5%-8% annual increase in global pharmaceutical sales over the next five years predicted by IMS Health, which also predicted that the health system overhaul may “spur fundamental change in the market” [due to new sales of drugs to previously uninsured Americans] starting 5 years from now.